The usa biopharmaceutical company Sage therapeutics announced on Wednesday that its experimental drug dalzanemdor failed to meet its primary objectives in a mid-stage study involving patients with the rare genetic neurological disease Huntington's disease. Based on these results, the company decided to terminate the development of dalzanemdor. Earlier this year, sage reported similar phase 2 study failures for dalzanemdor in Alzheimer's disease and Parkinson's disease. Last month, the company announced a strategic reorganization, laying off about 33% of its workforce.